Trial results
This results summary is not being shown. Voxsanity has temporarily withheld the AI generated plain English summary of these reported results. The registry and publication links are unchanged and lead to the results exactly as the sponsor reported them. How we use AI
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 24005613) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Ovarian Cancer Trial, Terminated
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- You have been diagnosed with invasive ovarian cancer, fallopian tube cancer, or peritoneal cancer (confirmed by laboratory testing of tissue), and your cancer has stopped responding to platinum-based chemotherapy, or has only partially responded to it.
- Your doctor plans to treat you with a specific chemotherapy drug called pegylated liposomal doxorubicin (50 mg/m²) for your returning cancer.
- If your cancer came back between 6 and 12 months after platinum-based chemotherapy, you may still be eligible, but only if your doctor has decided that further platinum-based chemotherapy is not a suitable option for you.
- You have already received at least one previous course of chemotherapy that included both a platinum-based drug and a taxane-based drug.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- You have cancer that has spread to the brain or is pressing on the spinal cord, unless it was treated at least 4 weeks ago and has been stable without steroid medication for at least 10 days.
- You are currently taking any medications that can affect the electrical activity of the heart in a specific way (confirm with trial site).
- You have received treatment with certain antibody-based medicines (mouse antibodies) in the last 3 months and your cancer is showing signs of progression based on a blood marker called CA-125 — unless your cancer can be measured by standard imaging scans or has been confirmed by tissue or fluid testing.
- You have already had more than two separate courses (lines) of chemotherapy.
- You have had chemotherapy or any other cancer treatment within the four weeks before joining the trial.
- You have had radiation therapy within the four weeks before joining the trial, unless it was given purely to relieve pain or symptoms.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial was run
These are the locations recorded on the registry, and they are a historical record: this trial is not enrolling, so they are not places you can join it.
Primary endpoints
Description (on the Basis of the Safety Set): Safety and Tolerability by Means of the Incidence and Type of Adverse Events (AEs).; Description (on the Basis of the Safety Set): Safety and Tolerability by Means of Clinically Significant Laboratory Abnormalities.; Description (on the Basis of the Safety Set): Safety and Tolerability by Means of the Incidence and Type of Adverse Events (AEs). Number of Participants With Dermatologic Skin Reactions Grade 3/4.; Description (on the Basis of the Safety Set): Safety and Tolerability by Means of the Incidence and Type of Adverse Events (AEs). Number of...
Other options
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.